| | Evaluation | Antioxidants | Omega 3 fatty acids |
| | With positive effects | AREDS report 8; Arch Ophthalmol 2001 (see [6])
AREDS2 RCT. JAMA 2005 (see [7])
Newsome et al., Arch Ophthalmol 1988 (see [66])
Richer et al., Optometry 2004 (see [67])
Stur et al., IOVS 1996 (see [68])
Newsome DA. Current Eye Res 2008 (see [69])
Richer S. J Am Optom Assoc 1996 (see [70]) | Feher et al., Ophthalmologica 2005 (see [71])
Chong et al., Arch Ophthalmol 2008 (see [72])
Christen et al., Arch Ophthalmol 2011 (see [73])
|
| | Without effects | AREDS2 RCT. JAMA 2005 (see [7])
Leeuwen et al., JAMA 2005 (see [74])
Flood et al., Ophthalmology 2002 (see [75])
Chow et al., Arch Ophthalmol 2004 (see [76])
Van den Langenberg et al., Am J Epidemiol 1998 (see [77])
Taylor et al., BMJ 2002 (see [79])
Moeller et al., Arch Ophthalmol 2006 (see [78])
Teikari et al., Acta Ophthalmol Scand. 1998 (see [83])
Omenn et al., N Engl J Med 1996 (see [86]) | AREDS2 RCT. JAMA 2005 (see [7])
Hodge et al., Ophthalmol 2006 (see [80])
Chong et al., BMJ 2007 (see [81])
Soused et al., Ophthalmology 2013 (see [82])
Heinonen et al., Annals of Epidemiology 2004 (see [84])
Tan et al., Ophthalmology 2008 (see [87])
Olson et al., Semin Ophthalmol 2011 (see [88]) |
| | With negative effects | AREDS report 8; Arch Ophthalmol 2001 (see [6])
AREDS2 RCT. JAMA. 2013 (see [7])
The ATBC Cancer Prevention Study Group. Ann Epidemiol 1994 (see [84])
Goodman GE et al., Cancer Epidemiol Biomarkers Prev 1993 (see [85])
Omenn et al., N Engl J Med 1996 (see [86]) | AREDS2 RCT. JAMA 2005 (see [7])
|
|
|
